When is chemotherapy recommended for multiple myeloma?

Multiple myeloma is a cancer of plasma cells in the bone marrow. Treatment is considered when the disease is active or is causing problems such as bone damage, anaemia, kidney impairment or high calcium. Some people with smouldering or inactive disease are monitored instead of starting treatment immediately.

Chemotherapy is commonly part of a combination regimen with medicines from other classes. The team considers blood and urine results, imaging, kidney function, age, fitness, other health conditions and whether an autologous stem-cell transplant is suitable. Treatment may be given in cycles, with rest periods for recovery.

Ask how the treatment plan addresses the myeloma and which medicines are being combined. Discuss stem-cell collection or transplant timing if relevant, as well as infection prevention, bone health, dental care, contraception and fertility. Tell the team about numbness, kidney disease, heart problems, previous cancer treatment and every medicine or supplement you take.

Keep appointments for blood tests and report changes in pain, weakness, thirst, urination, appetite or energy. These details can help the team identify treatment effects or complications early.

Contact the treatment team urgently for fever, chills or signs of infection. Seek emergency care for sudden leg weakness, loss of bladder or bowel control, severe back pain, confusion, fainting, chest pain, severe breathlessness or uncontrolled bleeding. Marked thirst, repeated vomiting or much less urine can signal a metabolic or kidney problem and needs prompt assessment.

Is my myeloma active, and what finding makes treatment necessary now? What is the role of chemotherapy in my combination plan? Is transplant assessment appropriate? How will kidney function, blood counts and bone health be monitored?